Screener
Dianthus Therapeutics DNTH Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $627,667 | $51,087 |
| Short-term investments | 483,592 | 353,208 |
| Accounts receivable, net | 1,230 | 52 |
| Prepaid expenses and other current assets | 7,422 | 5,091 |
| Total current assets | 1,119,911 | 409,438 |
| Long-term investments | 113,868 | 110,135 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's short-term investments?
- Dianthus Therapeutics (DNTH) reported short-term investments of $483.59M in Q1 2026.
- How has Dianthus Therapeutics's short-term investments changed year-over-year?
- Dianthus Therapeutics's short-term investments increased by 91.1% year-over-year, from $253.11M to $483.59M.
- What is the long-term trend for Dianthus Therapeutics's short-term investments?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's short-term investments has grown at a 31.3% compound annual growth rate (CAGR), from $90.68M to $353.21M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Dianthus Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude